# Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

> **NCT00359463** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 33 (actual)

## Conditions studied

- Purpura, Thrombocytopaenic, Idiopathic

## Interventions

- **DRUG:** eltrombopag

## Key facts

- **NCT ID:** NCT00359463
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04-18
- **Primary completion:** 2007-03-07
- **Final completion:** 2007-03-07
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00359463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00359463, "Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00359463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*